
Teva has received permission from the FDA to market rasagiline(Azilect) for the treatment of Parkinson's disease (PD). The newmolecular entity is a monoamine oxidase type B inhibitor that worksby blocking the breakdown of dopamine. Rasagiline was approved asan initial single-drug treatment in early PD and in addition tolevodopa in more advanced patients. Like other MAOIs, rasagilinehas the potential to cause a hypertensive crisis if a patientconsumes tyramine-containing foods while on therapy. The efficacyof the new drug was tested in 404 patients with early disease and1,100 patients with more advanced PD.